GleamWall
中文EN

GRCE Grace Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1444192 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-173.9%
TTM EPS YoY-118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-36.2%
ROA-34.5%
ROIC (approx.)-46.7%
Asset turnover—

Leverage & solvency

Liabilities / assets3.8%
Debt / equity0.00x
Current ratio13.61x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-20.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue————————
R&D expense$885,000$697,000$420,000$462,000$568,000$955,000$1.63M$2.19M
SG&A expense$1.41M$1.69M$2.59M$1.99M$1.96M$2.13M$1.55M$1.51M
Operating income-$2.29M-$15.92M-$3.01M-$2.45M-$2.53M-$3.09M-$3.18M-$3.70M
Pretax income-$2.14M-$15.79M-$2.88M-$2.31M-$938,000-$3.36M-$382,000-$4.76M
Income tax-$8,000$0-$1.70M$0$0$0-$1.02M-$605,000
Net income-$2.13M-$15.79M-$1.18M-$2.31M-$938,000-$3.36M$636,000-$4.16M
EBITDA-$2.29M-$15.91M-$3.01M-$2.45M-$2.53M-$3.09M-$3.18M-$3.70M
EPS (basic)-0.11-0.91—-0.14-0.06-0.21—-0.36
EPS (diluted)-0.11-0.91—-0.14-0.06-0.21—-0.36
Weighted avg. shares (diluted)20.12M17.27M—16.93M15.92M15.92M—11.51M
Balance sheet
Cash & equivalents$21.31M$13.76M$16.98M$18.67M$16.86M$20.00M$22.13M$11.05M
Current assets$21.96M$14.33M$17.38M$19.21M$17.30M$20.52M$22.71M$11.94M
PP&E, net——$8,000———$15,000—
Goodwill$8.14M$8.14M$8.14M$8.14M$8.14M$8.14M$8.14M$8.14M
Intangibles$27.59M$27.59M$41.13M$41.13M$41.13M$41.13M$41.13M$41.13M
Total assets$57.70M$50.07M$66.65M$68.49M$66.58M$69.81M$71.99M$61.22M
Current liabilities$1.61M$1.25M$2.15M$1.28M$1.25M$2.31M$1.93M$1.97M
Total liabilities$2.22M$1.86M$2.76M$3.60M$3.76M$6.25M$5.38M$9.09M
Shareholders' equity$55.48M$48.21M$63.90M$64.89M$62.82M$63.55M$66.61M$52.14M
Shares outstanding21.04M16.27M16.02M15.47M14.13M13.83M13.72M10.14M
Cash flow statement
Operating cash flow-$1.78M-$3.22M-$1.70M-$2.23M-$3.14M-$1.80M-$2.95M-$4.12M
Investing cash flow——$0$0$0$0$0$15,000
Financing cash flow$9.34M$0$0$4.04M$0-$327,000$14.03M$0
Depreciation & amortization$1,000$2,000$2,000$3,000$0$2,000$2,000$2,000
Stock-based compensation$197,000$105,000$182,000$108,000$206,000$302,000$130,000$160,000

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.